Navigation Links
AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited
Date:12/5/2011

VIENNA, December 5, 2011 /PRNewswire/ --

AFFiRiS AG announced today that Ali Alloueche is taking senior responsibility for their expanding business development activities. This new management position has been established as a result of the growing development pipeline of the Viennese biopharmaceutical company. As a member of the management team, Ali Alloueche will strategically and operationally support the development of AFFiRiS AG. Before joining AFFiRiS, Ali Alloueche was Head of External R&D at the leading vaccine manufacturer GlaxoSmithKline Biologicals, Belgium.

AFFiRiS AG has appointed Ali Alloueche as Chief Business Officer. In this position he will oversee business activities, strategic alliances and partnerships arising from the continuously growing pipeline of the Viennese biopharmaceutical company. Based on strong IP-positions and its AFFITOME©-technology, AFFiRiS has a diversified pipeline with four vaccine candidates currently in clinical phases and other attractive candidates in pre-clinical stage. Target indications include Alzheimer's, Parkinson's, Atherosclerosis and Hypertension - all diseases with unmet medical needs and attractive market potential.

Prior to joining AFFiRiS Ali Alloueche was Head External R&D at GlaxoSmithKline Biologicals in Belgium. In this position he expanded the company's R&D pipeline and extended its network of collaborators and business partners. In this role, he identified AFFiRiS's Alzheimer's vaccine candidates for GlaxoSmithKline - an activity in 2007 that culminated in a up to EUR 430 million-deal between both companies in October 2008. Prior to GlaxoSmithKline, Ali Alloueche was Research Director at Novartis Vaccines and Diagnostics in Italy and Head Translational Medicine and Scientific Affairs. Commenting on his new position, Ali Alloueche says: "AFFiRiS is one of the most dynamic biopharmaceutical companies in Europe. The company's focus on clinical programs and its robust
'/>"/>

SOURCE AFFiRiS AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
5. AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing
6. AFFiRiS AG: Vaccination Against Hypertension is Development Project No. 4 and has Already Been Awarded an FFG Grant of up to EUR 1.2 Million
7. AFFiRiS AG: Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board
8. Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure
9. Lockheed Martin Invests in Smart Grid Research and Development at Penn State University
10. Burrill & Company Invests in Taiwan Liposome Company
11. University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China ... the "Company"), a leading fully integrated plasma-based biopharmaceutical ... announced that its majority-owned subsidiary, Shandong Taibang Biological ... ("GMP") certification from the China Food and Drug ... production facility. As previously disclosed in the Company,s ...
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... The Center for Professional Innovation ... training across the life sciences industry, has partnered with ... to provide the organization's members with discounted classroom courses, ... the more than 350 sessions across 80 course titles. ... when registering for a public course at ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... present a company update at the Morgan Stanley Healthcare Conference in New ... , , Interested parties may access a live ... BioMarin website, www.BMRN.com . A replay of the ...
... , NEW BRUNSWICK, N.J., Sept. 8 ... SNT ) today announced that the Company will be presenting at ... held at the New York Palace Hotel from September 9th - ... will deliver the Company,s corporate presentation on Friday, September 11th, at ...
... CAMBRIDGE, Massachusetts, September 8 Shire plc,(LSE: SHP, ... company, is,committed to doing everything possible to assist Gaucher ... is pleased to be,able to provide velaglucerase alfa well ... wide. , In the U.S., ...
Cached Biology Technology:BioMarin to Present at the Morgan Stanley Healthcare Conference 2Senesco Technologies to Present at 11th Annual Rodman & Renshaw Healthcare Conference 2Update on velaglucerase alfa 2Update on velaglucerase alfa 3
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... of the American Medical Society ("Medical News & ... Associate Professor Sergei Adamovich, a biomedical engineer. Adamovich and ... and Eugene Tunik, PhD, PT, at the University of ... robotic and virtual reality-based video game therapies to help ...
... that the animal with the most genes--about 31,000--is the ... By comparison, humans have about 23,000 genes. Daphnia is ... The water flea,s genome is described in a ... the Daphnia Genomics Consortium, an international network of scientists ...
... provided the first conclusive evidence that cannabis use significantly hastens ... brain development with possible life-long consequences. The ... smoking cannabis is associated with an earlier onset of psychotic ... an international team including Dr Matthew Large, from the University ...
Cached Biology News:JAMA features NJIT biomedical engineer helping stroke patients 2JAMA features NJIT biomedical engineer helping stroke patients 3The most genes in an animal? Tiny crustacean holds the record 2The most genes in an animal? Tiny crustacean holds the record 3Cannabis linked to earlier onset of psychosis 2
Goat polyclonal to NIR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SWARGPPKFESVP, corresponding to C terminal amino acids 962-974 of NIR1. Entrez Gene ID: 83394 ...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Biology Products: